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Gephyrin was originally identified as a membrane-associated protein that is essential for the postsynaptic localization
of receptors for the neurotransmitters glycine and GABAA. A sequence comparison revealed homologies between
gephyrin and proteins necessary for the biosynthesis of the universal molybdenum cofactor (MoCo). Because
gephyrin expression can rescue a MoCo-deficient mutation in bacteria, plants, and a murine cell line, it became
clear that gephyrin also plays a role in MoCo biosynthesis. Human MoCo deficiency is a fatal disease resulting in
severe neurological damage and death in early childhood. Most patients harborMOCS1 mutations, which prohibit
formation of a precursor, or carryMOCS2 mutations, which abrogate precursor conversion to molybdopterin. The
present report describes the identification of a gephyrin gene (GEPH) deletion in a patient with symptoms typical
of MoCo deficiency. Biochemical studies of the patient’s fibroblasts demonstrate that gephyrin catalyzes the insertion
of molybdenum into molybdopterin and suggest that this novel form of MoCo deficiency might be curable by
molybdate supplementation.
In mammals, molybdenum cofactor (MoCo) is essential
for the activity of sulfite oxidase, xanthine dehydro-
genase, and aldehyde oxidase (Johnson and Wadman
1995). Mutations affecting theMoCo biosynthetic path-
way result in the simultaneous loss of all molybdoen-
zyme activities. The cerebral atrophy associated with
MoCo deficiency (MIM 252150) is also observed in iso-
lated sulfite oxidase deficiency (MIM 272300) and can
be attributed exclusively to the loss of this enzyme. Both
the isolated and the combined form are inherited as au-
tosomal recessive traits, without any symptoms in het-
erozygous carriers, and they come to clinical attention
because of untreatable neonatal seizures, with opistho-
tonos and facial dysmorphism. The combined form is
found more often, with ∼100 cases known worldwide.
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We had examined 42 of these patients and had found
mutations inMOCS1(MIM 603707) (Reiss et al. 1998b)
or MOCS2 (MIM 603708) (Stallmeyer 1999a) in 40
cases (Reiss et al. 1998a, 1999; Reiss 2000).
We studied the last of three affected infants born to
a Danish mother and father who were cousins. All three
died in the neonatal period (day 12, 29, and 3, respec-
tively), with symptoms identical to MoCo deficiency.
Three other pregnancies of the mother resulted in two
healthy sibs and one spontaneous abortion. There was
no family history of genetic disease, and all three affected
infants had a normal karyotype. The first infant was a
boy, and the other two were girls. All showed hypotonia
combined with hyperreflexia, as well as tonic-clonic con-
vulsions. Fibroblasts of the third infant, the patient, were
used to verify a MoCo deficiency by biochemical and in
vitro complementation assays and to isolate DNA for
genetic analysis. The study was approved by the ethics
committee of the Medical Faculty of Go¨ttingen. Com-
plete sequencing of allMOCS1 andMOCS2 exons, plus
adjacent splice-junction sequences, did not reveal a
disease-causing mutation in the patient. The human
MOCS3 cDNA and genomic sequence, encoding the
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Figure 1 Gephyrin and MoCo biosynthesis. a, Schematic rep-
resentation of gephyrin and homologous proteins. The domain sym-
bols G and E correspond to the respective bacterial operons. b, Illus-
tration of the last step in MoCo biosynthesis, the gephyrin-catalyzed
insertion of molybdenum into molybdopterin.
Figure 2 Detection of a gephyrin gene deletion. a, PCR amplification of individual exons (1–22) from genomic DNA of a control (top)
and the patient (bottom). DNA was isolated from fibroblasts with standard phenol/chloroform extraction methods. PCR (40 cycles at 94C for
45 s, at 50C–60C for 45 s, and at 72C for 2 min after an initial incubation of 15 min at 94C) was done with HotStarTaq PCR master mix
(Qiagen) and exon-flanking primers (table 1). b, Nested PCR cDNA amplification from exon 1 to exon 4 after reverse transcription. Total RNA
was isolated from fibroblasts with an RNeasy minikit combined with QIAshredder columns (Qiagen). First-strand synthesis was done with the
Omniscript RT kit (Qiagen), including RNasin (Promega) and a sequence-specific primer in a 20-ml volume. In a first PCR of 25 cycles, 10 ml
of this reaction was used, with the conditions specified above, and 1 ml of first-round PCR product was the template for a second-round PCR
with 40 cycles and two nested primers. B p blank (no template); C p healthy control; M p size marker (100-bp ladder) (New England
Biolabs); P p patient.
molybdopterin synthase sulfurylase (Appleyard et al.
1998), were also found to be devoid of mutations in the
patient’s DNA (data not shown).
We analyzed the GEPH gene (MIM 603930) for the
receptor-clustering neuroprotein gephyrin (Kirsch et al
1973; Essrich et al. 1998; Kneussel and Betz 2000) as
a candidate gene for the MoCo deficiency in this family.
Gephyrin consists of two distinct protein domains sep-
arated by a linker sequence (fig. 1a). The N-terminal
domain of gephyrin is homologous to the bacterial pro-
tein MogA, and the C-terminal domain is homologous
to bacterial MoeA, both proteins being involved in the
biosynthesis of MoCo (Stewart 1988). This architecture
is shared by the Drosophila protein Cinnamon (Kamdar
et al. 1994) and, with a reversed domain order, the plant
protein Cnx1 (Stallmeyer et al. 1995). The bacterial
moaB gene is also homologous to the 5′ region of the
GEPH cDNA, as well as to the bacterial mogA gene.
However, no bacterial mutant and no function is known
formoaB. The moeA gene product is believed to activate
molybdenum before its incorporation into molybdop-
terin (Hasona et al. 1998; Kuper et al. 2000). Bacterial
mogA mutants can produce active MoCo in media sup-
plemented with high concentrations of molybdate (Stew-
art and MacGregor 1982). This “molybdenum rescue”
is also observed for the corresponding plant mutants
(Stallmeyer et al. 1995) and the MoCo-deficient murine
cell line L929 (Falciani et al. 1994).
Geph cDNA derived from rats could restore molyb-
denum-repairable plant mutants and bacterial mogA
mutants, as well as L929 cells (Stallmeyer et al. 1999b).
Likewise,Geph knockout mice showed the expected ab-
sence of synaptic glycine-receptor clustering and devel-
oped symptoms identical to those of MoCo deficiency
(Feng et al. 1998). Therefore, gephyrin combines an ev-
olutionarily novel function (neuroreceptor clustering)
with a conserved old function (MoCo biosynthesis), the
latter being essential for activation (E domain) and in-
sertion (G domain) of molybdenum into molybdopterin,
thereby forming the biologically active cofactor (fig. 1b).
The rat Geph cDNA sequence (Prior et al. 1992) was
used to screen the nonredundant GenBank database for
human cDNA sequences with the homology search pro-
gramAdvanced BLAST. A 4,193-bp cDNA clone derived
from brain tissue contains the complete coding sequence
for human gephyrin, with the start codon at position
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Table 1
Oligonucleotides Used in Study of Patient with Gephyrin Gene
Deletion
Methoda Primer Sequence
EA:
E1 G1F 5′-CCTAGCTGTCGCGCTCTCCT-3′
G1R 5′-TCCCGAGGCCGCAGAGAAGG-3′
E2 G2F 5′-GGTCAGCAATAGCTTAAATG-3′
G2R 5′-CTCTTTTGAGAAAAGGAACAC-3′
E3 G3F 5′-GCATTCTGATGGTAATGGCA-3′
G3R 5′-ACCCCTCACCAAGATGCTAA-3′
E4 G4F 5′-GGGATGTTTTGAGCAAGCAG-3′
G4R 5′-CCATGATTAGTTTAATCCTTG-3′
E5 G5F 5′-GTGGGTTTTACTAGTCTGAC-3′
G5R 5′-ACAGTTCACCTAGCAAATGG-3′
E6 G6F 5′-CTTAATGTATTTAAACCGGGC-3′
G6R 5′-TTTGGCTCCCTAACTTTCAC-3′
E7 G7F 5′-CAGTTTGATTGCCACCATCT
G7R 5′-TTACCTGTGGGTCCTTTAGG-3′
E8 G8F 5′-AAGGGGGTCTTGATTCTACA-3′
G8R 5′-CCCAGATTACTATAGAAGAGC-3′
E9 G9F 5′-ACCTCAGGAGCTTGCCCATT-3′
G9R 5′-AAGCTCTAGTTCAGCAGCCC-3′
E10 G10F 5′-GTCATTGCCACTTTTTAATCA-3′
G10R 5′-CAGGAAAACTGTGCATTAATG-3′
E11 G11F 5′-CAAGCACTCATGCCCATCTT-3′
G11R 5′-CAGTGCCTGATTATGTTTAAG-3′
E12 G12F 5′-CTTGTTCCATGCTGTAGGTC-3′
G12R 5′-TTCCACTAAACTGATAGGAGA-3′
E13 G13F 5′-CTTTTCCTTTGCAGCAGCAA-3′
G13R 5′-ACTGCCATAGGAACAACAGC-3′
E14 G14F 5′-TATCCTGGGCCTATCTGATG-3′
G14R 5′-GCCAGGGTTTCCTGAGTAAA-3′
E15 G15F 5′-CACTAAAGTTTCCCTCTGAG-3′
G15R 5′-CAACACAGAACATATGTCAG-3′
E16 G16F 5′-TATGCAACATTAACCTAATAG-3′
G16R 5′-ATGAGTATTCCAAAAACTCG-3′
E17 G17F 5′-GCCTATTAGTGAATAAGGCG-3′
G17R 5′-AGATGCCTACCAGACCACAG-3′
E18 G18F 5′-TCATTTAAAGTGTTGAAAGTC-3′
G18R 5′-CCCATATATGAGATAACAAGA-3′
E19 G19F 5′-AAAACACTGGAGTACTTAATG-3′
G19R 5′-CCAGAAAAAGGAAAGGAAAC-3′
E20 G20F 5′-TAGACAGACATAATTATTTGGC-3′
G20R 5′-TTAGGAAATCATATCCCTAAC-3′
E21 G21F 5′-GTCCACTGTATTCTTTGCAC-3′
G21R 5′-CAGGATAGGTGTCTAGGAA-3′
E22 G22F 5′-AGGGCCCAACTGTATACGCC-3′
G22R 5′-GCTTTCTCCTGCTGGTGACC-3′
RT-PCR:
RT RT1 5′-CAGGGCCATCCCTGGTGCTT-3′
PCR1 G1F 5′-CCTAGCTGTCGCGCTCTCCT-3′
RT1 5′-CAGGGCCATCCCTGGTGCTT-3′
PCR2 RT2 5′-TTCTCCCGGCTCCTGTCAGT-3′
RT3 5′-TCGTGGTGCAAATCCTGTTC-3′
a A p amplification; E p exon.
Figure 3 a, Sequence analysis of the RT-PCR product of control
(top) and patient (bottom). Sequencing was done commercially
(SeqLab) after purification of the amplification products with the QIA
quick PCR purification kit (Qiagen) with the PCR primers and dideoxy
fluorescent dye terminators (ABI). The transition from exon 1 to exon
2 or 4, respectively, is indicated by the arrow. b,Western blot analysis
of gephyrin expression in crude protein extracts using a polyclonal
anti-gephyrin antibody. Crude protein extracts were prepared from
fibroblasts, separated by SDS-PAGE using a 7.5% polyacrylamide gel,
and blotted onto a polyvinyldiene fluoride membrane. Positive controls
were recombinant rat Geph P1 and P2 splice forms expressed in Es-
cherichia coli (G.S., unpublished data). A primary polyclonal antibody
generated against recombinant rat gephyrin P1 protein was used (di-
luted in serum at 1:2000), followed by chemiluminescent detection
(secondary antibody, Promega; ECL system, Amersham/Pharmacia).
Lane 1, recombinant rat gephyrin P2 (20 ng); lane 2, recombinant rat
gephyrin P1 (20 ng); lane 3, size marker (labeled in kDa); lane 4,
positive control (18 mg); lane 5, patient with gephyrin gene deletion
(20 mg).
1122 and the stop codon at position 3330. The nucleo-
tide and amino acid sequence homologies are 93% and
100%, respectively. The human cDNA sequence was
used to identify the genomic sequences in the HTGS
(high throughout genomic sequences) library. A homol-
ogy search revealed that the gene is located on chro-
mosome 14 and consists of 22 exons covering a genomic
region of375 kbp. These genomic sequences were used
as primer targets to amplify all exons individually, plus
each of their adjacent splice-signal sequences (table 1).
Amplification of patient and control DNA revealed a
deletion encompassing exons 2 and 3 in the patient (fig.
2a). This deletion was verified by reverse transcriptase
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Figure 4 Biochemical characterization of fibroblasts with the
gephyrin gene deletion. a, HPLC detection of the molybdopterin de-
rivative “form A” in crude fibroblast extracts of a healthy control
subject (top), a patient with a MOCS1 mutation as negative control
(middle), and the patient with the gephyrin gene deletion (bottom).
Molybdopterin was detected by conversion to its stable oxidation
product form A-dephospho. Oxidation (1 mg protein per sample) with
I2/KI, QAE-sephadex chromatography and HPLC analysis on a C18
reversed-phase column were performed as described elsewhere
(Schwarz et al. 1997). b, nit-1 reconstitution assay for the detection
of active MoCo (Mo) and total molybdopterin, including both the
metal-free and metal-loaded pterin (Mo) of a control (left) and of
the patient without (middle) and with (right) molybdate supplemen-
tation of the medium. c, Sulfite oxidase activity of control fibroblasts
(left), the patient’s fibroblasts grown on normal medium (middle) and
the patient’s fibroblasts grown on medium supplemented with molyb-
date (10 mM) (right). Neurospora crassa nit-1 extract was prepared
as described elsewhere (Nason et al. 1971). The assay was performed
in a 90-ml (Mo) or a 180-ml (Mo) volume containing 30 ml or 60
ml, respectively, of nit-1 extract freshly filtered on gel (Nick columns;
Amersham/Pharmacia) in the presence of 2 mM reduced glutathione.
Protein extracts from fibroblasts were prepared in 50 mM sodium
phosphate, 200 mM NaCl, 5 mM EDTA (pH 7.2) and were added in
various amounts (20–120 ml) to the nit-1 extract, according to the
linear range of the assay. Total molybdopterin content was determined
by performing the reconstitution in the presence of 10 mM sodium
molybdate. MoCo was detected in the absence of external molybdate.
Complementation was carried out anaerobically overnight at 4C. Af-
ter addition of 20 mM NADPH for 10 min, reconstituted NADPH-
nitrate reductase activity was determined. One nit-1 unit is defined as
the A540 of 1.0/30 min nitrate reductase reaction time. Sulfite oxidase
activity was determined as described elsewhere (Johnson et al. 1991).
PCR, in which exclusively truncated transcripts were de-
tected (fig. 2b), followed by sequencing of the amplifi-
cation products (fig. 3a). On the mRNA level, this de-
letion results in a frameshift after only 21 codons of the
normal coding sequence. Therefore, neither of the two
gephyrin domains (fig. 1) is expressed.Western blot anal-
ysis confirmed the complete absence of gephyrin protein
in crude extracts of the patient’s fibroblasts, whereas the
expression of at least two splice variants (Prior et al.
1992) can be seen in control cells (fig. 3b).
Because of the presumed function of gephyrin in
MoCo formation (fig. 1b), loss of this protein should
result in the accumulation of molybdenum-free molyb-
dopterin. We demonstrated the presence of the fluores-
cent oxidation product of molybdopterin (“form A”)
(Johnson and Wadman 1995) by high-performance liq-
uid chromatography analysis (HPLC) (fig. 4a). Biolog-
ically active molybdopterin andMoCo can be quantified
by the in vitro nit-1 reconstitution assay, which is based
on the transfer of MoCo to the nitrate reductase apo-
protein of the Neurospora crassa nit-1 mutant (Nason
et al. 1971). Depending on presence or absence of mo-
lybdate in the assay, it can be used for the detection of
total molybdopterin (Mo), including all forms of the
pterin andMoCo (Mo). HPLC analysis of the patient’s
cells shows an increased level of molybdopterin (fig. 4b),
compared with control cells. Active MoCo could be de-
tected only in control cells and in those patient cells that
were supplemented with 1 mMmolybdate (fig. 4b). This
molybdate repair of the cofactor could also be demon-
strated by the regained sulfite oxidase activity (fig. 4c).
After the primary sequence of the receptor-associated
gephyrin revealed homologies to MoCo biosynthetic en-
zymes, it appeared counterintuitive that a eukaryotic
protein might have two such different functions as (i) a
structural role in receptor clustering and (ii) a biosyn-
thetic activity in MoCo formation. It has been suggested
that two bacterial biosynthetic genes (mogA and moeA)
have been fused during evolution to form a multidomain
protein with a novel function (Kamdar et al. 1994; Stall-
meyer et al. 1995; Feng et al. 1998). This has happened
under persistence of the biosynthetic activities, whose
abrogation, as shown here, results in a lethal malfunc-
tion.Moreover, the fusion of the same prokaryotic genes,
in reversed orientation, in higher plants (Stallmeyer et
al. 1995) (fig. 1a) demonstrates that there is a strong
selective pressure for this convergent development in
eukaryotes.
The gravity of the disease in the family described here
is very similar to the serious phenotype seen in theGeph
knockout mice (Feng et al. 1998). Such mice could be
used to test whether MoCo-deficient patients with
GEPH mutations could be treated successfully by ad-
ministering high concentrations of molybdate. In at-
tempts reported elsewhere, administration of an oral
(Duran et al. 1978; Munnich et al. 1983; Endres et al.
1988) or an intravenous (Bamforth et al. 1990) molyb-
date supplementation toMoCo-deficient patients did not
lead to any clinical or biochemical improvement. These
patients, however, have not been examined genetically,
and, on the basis of the observed mutation frequencies,
it seems likely that they carried mutations in the “non-
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repairable” genesMOCS1 orMOCS2 (Reiss 2000). The
dysfunction of gephyrin as a receptor-clustering mole-
cule in the postsynaptic membrane cannot be restored
by these means. Hyperekplexia (MIM149400), as a con-
sequence of isolated receptor dysfunction, is a relatively
mild neurological disorder, which can be ameliorated by
pharmaceutical agents (Andrew and Owen 1997). These
drugs could be combined with a molybdate therapy in
gephyrin-deficient patients to treat the synaptic receptor
dysfunction, as well as the biosynthetic deficiency. As in
the other forms of MoCo deficiency, the most successful
approaches may include prenatal treatment to prevent
neurological damage.
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